May 18, 2024, 00:16
Luis E. Raez: Analysis of PRO data from the landmark LIBRETTO-001 trial
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post on X:
“In this analysis of PRO data from the landmark LIBRETTO-001 trial published by Alexander Drilon, Vivek Subbiah, Benjamin Besse, Ben Solomon, Keunchil Park, Herbert Loong and others, the majority of patients with RET cancers that we treated remained stable or improved demonstrating the favorable HRQoL during long-term treatment with selpercatinib.”
Read further.
Source: Luis E. Raez/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 12, 2024, 03:45
Oct 11, 2024, 21:08
Oct 11, 2024, 21:05
Oct 11, 2024, 21:00
Oct 11, 2024, 20:54